Cargando…

CD4 cell response to interval therapy with natalizumab

Natalizumab treatment alters peripheral CD4 cells counts in multiple sclerosis (MS) patients, providing a way to monitor the pharmacodynamic effects of the drug. The study was undertaken to assess whether CD4 cell counts correlate with different phases of natalizumab treatment of relapsing MS patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berkovich, Regina, Togasaki, Daniel M, Cen, Steven Y, Steinman, Lawrence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435710/ https://www.ncbi.nlm.nih.gov/pubmed/26000328 http://dx.doi.org/10.1002/acn3.190

Ejemplares similares

Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab
por: Berkovich, Regina, et al.
Publicado: (2021)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Improving risk‐stratification of natalizumab‐associated PML
por: Tugemann, Bastian, et al.
Publicado: (2021)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic
por: Magro, Giuseppe, et al.
Publicado: (2022)

Requirement of CD4 Help for Induction of CD8 T Cell Response Specific for Virally Derived H60
por: Ryu, Su Jeong, et al.
Publicado: (2012)

Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells
por: Spadaro, Michela, et al.
Publicado: (2015)

Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic
por: Bringeland, Gerd Haga, et al.
Publicado: (2021)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab
por: Magro, Giuseppe, et al.
Publicado: (2021)

Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab
por: Gundacker, Nathan D., et al.
Publicado: (2016)

Eosinophils Modulate CD4(+) T Cell Responses via High Mobility Group Box-1 in the Pathogenesis of Asthma
por: Shim, Eun-Jin, et al.
Publicado: (2015)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
por: Bringeland, Gerd Haga, et al.
Publicado: (2020)

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
por: Pelle, Juliette, et al.
Publicado: (2023)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
por: Jamroz-Wiśniewska, Anna, et al.
Publicado: (2021)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Identification of CD4(+) T cell biomarkers for predicting the response of patients with relapsing-remitting multiple sclerosis to natalizumab treatment
por: Fagone, Paolo, et al.
Publicado: (2019)

Ribavirin Does Not Impair the Suppressive Activity of Foxp3(+)CD4(+)CD25(+) Regulatory T Cells
por: Lee, Jeewon, et al.
Publicado: (2013)

Cerebrospinal Fluid Aquaporin-4 Antibody Levels in Neuromyelitis Optica Attacks
por: Sato, Douglas Kazutoshi, et al.
Publicado: (2014)

Anti-CD137 mAb Deletes Both Donor CD4(+) and CD8(+) T Cells in Acute Graft-versus-host Disease
por: Kim, Juyang, et al.
Publicado: (2011)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

Trichinella spiralis Infection Suppressed Gut Inflammation with CD4(+)CD25(+)Foxp3(+) T Cell Recruitment
por: Cho, Min Kyoung, et al.
Publicado: (2012)

Identification of patient-specific CD4(+) and CD8(+) T cell neoantigens through HLA-unbiased genetic screens
por: Cattaneo, Chiara M., et al.
Publicado: (2023)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Hematologic reference intervals of Danish sows at mid-gestation
por: Bhattarai, Sheeva, et al.
Publicado: (2019)

Learned interval time facilitates associate memory retrieval
por: van de Ven, Vincent, et al.
Publicado: (2017)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

Enrichment of milk with magnesium provides healthier and safer dairy products
por: Ben-Ishay, Noa, et al.
Publicado: (2017)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

Chinese Pediatric Reference Intervals for Serum Cortisol on IMMULITE 2000
por: Wang, Ling-Li, et al.
Publicado: (2018)

Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment
por: Nguyen Ky, Mélanie, et al.
Publicado: (2023)

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
por: Reid, Carl E., et al.
Publicado: (2011)

CD4(+) T(h) immunogenicity of the Ascaris spp. secreted products
por: Ebner, Friederike, et al.
Publicado: (2020)

Direct Measurement of Creatinine Clearance over a Short Interval in Intensive Care Settings
por: Law, Lawrence SC, et al.
Publicado: (2021)

Increased Th17 cells in flow cytometer-sorted CD45RO-positive memory CD4 T cells from patients with systemic lupus erythematosus
por: Liu, Ming-Fei, et al.
Publicado: (2014)

Reference Intervals for Plasma Amyloid β in Korean Adults Without Cognitive Impairment
por: Kim, Min-Young, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9ch7bjjsbu2q1ogrhfkdaiubsj